Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this phase 1 trial is to determine the maximum tolerated dose (MTD),
food effect, safety and tolerability of oral ONC206 in patients with recurrent, primary CNS
neoplasms.